I

Invivyd

Develops monoclonal antibodies for viral protection

Vice President, Associate General Counsel, Infectious Disease Franchise

Full-Time
$309k - $383k
Expert
JD
New Haven, CT, USA
HybridAt least three days per week onsite in New Haven; periodic travel is required.
LegalLegal Counsel & Legal Support

About the job

Requirements
  • Have a Juris Doctor (J.D.) from an ABA-accredited law school; be a licensed attorney in at least one U.S. state and in good standing in all states where you are licensed; and have the ability to obtain Connecticut in-house counsel registration.
  • Have a minimum of 10 years of relevant experience with a pharmaceutical or biopharmaceutical company, which can be combined with relevant law firm experience, providing relevant life sciences advice, counsel, and support to pharmaceutical or biopharmaceutical companies.
  • Demonstrate expertise in relevant federal and state laws, regulations, rules, guidance, industry codes, and principles impacting pharmaceutical manufacturers, including law concerning drug labeling, advertising and promotion, scientific exchange, market access communications, government reimbursement, and product liability.
  • Demonstrate experience supporting regulatory and commercialization teams, including providing legal counsel on Medical, Legal, Regulatory review committees, development and implementation of promotional activities, market access communications, drug labeling, and scientific exchange.
  • Have experience supporting regulatory affairs and drug safety in pharmaceutical development and ongoing obligations.
  • Have knowledge of the enforcement landscape, including relevant industry litigation, settlements, and corporate integrity agreement obligations.
  • Have demonstrated senior leadership and personnel management skills and experience.
  • Demonstrate experience with digital and social media policies, regulations, guidance, and industry practice.
  • Have experience drafting, reviewing, and/or interpreting written compliance materials and advising upon them.
  • Demonstrate critical thinking and the ability to connect issues across broad areas, analyze complex, novel, and challenging issues, clearly articulate risks and potential consequences, and provide timely, compliant, practical, creative, and implementable solutions.
  • Have strong written and verbal communication skills, leadership skills, problem-solving and decision-making skills, and the ability to devise creative solutions to challenging problems.
  • Demonstrate accountability, ownership, self-management, sound judgment, ethics, professional maturity, and the ability to identify issues, opportunities, and solutions for business and legal team success.
  • Be collaborative and able to work independently and as a teammate in a remote environment and across the Legal and Compliance Department and other functions.
  • Be able to learn the business and science and build relationships with clients to prioritize and deliver results.
  • Be willing to support the legal team and business on broader initiatives as needed.
  • Maintain a high-quality and continuous-improvement orientation and stay current with relevant laws, regulations, guidance, policies, and codes.
  • Be able to work at the New Haven, Connecticut office at least three days per week; onsite presence is an essential job function.
  • Be able to travel periodically for company off-site meetings, field ride-alongs or program monitoring, and meetings such as conferences and congresses.
Responsibilities
  • Provide strategic, operational, and tactical legal counsel and business advice related to development and commercialization of the company's products and product candidates.
  • Advise clients on FDA and global regulatory authority matters and compliance with laws, rules, regulations, guidance, and industry standards throughout a product lifecycle, including product development, regulatory submissions, advertising and promotion, and drug safety.
  • Provide legal counsel on healthcare laws, including the Federal Anti-Kickback Statute, Federal Food, Drug, and Cosmetic Act, False Claims Act, PhRMA Code, Federal Trade Commission requirements, Health Insurance Portability and Accountability Act, CAN-SPAM, state laws on physician gifts and meals, Sunshine Act, state price transparency reporting, product liability statutes, and related healthcare legal obligations.
  • Provide legal advice and business counsel, and create and review materials such as informed consent forms, ClinicalTrials.gov postings, FDA correspondence, and submissions for Clinical, Clinical Operations, Regulatory Affairs, and Pharmacovigilance relating to clinical trial programs and drug development.
  • Provide legal advice, business counsel, and training to Marketing on marketing strategies, activities, programs, and trainings; serve as Legal representative on the company committee reviewing advertising and promotional strategies and materials and digital and social media initiatives; and work with clients to develop compliant strategies for interacting with healthcare providers and other stakeholders.
  • Provide legal advice, business counsel, and training to Market Access, including on payer strategies, pre-approval information exchange materials, distribution models and materials, patient support programs, health economics and outcomes research studies, and communications.
  • Provide legal advice, business counsel, and training to Medical Affairs on proactive and reactive communications, including scientific exchange, research planning and support, publications, presentations, engagements, and other activities; serve as Legal representative on the company committee reviewing selected scientific exchange.
  • Review materials for the Corporate Affairs communications team, including social media posts.
  • Work with Legal and Compliance colleagues to provide consistent and efficient legal and compliance support; support the creation, review, updating, and training of corporate and healthcare compliance policies, standard operating procedures, rules of engagement, laws, regulations, guidance, and codes.
  • Provide and coordinate legal support as a member of cross-functional teams.
  • Represent the Legal department on cross-functional initiatives and collaborate with Legal department colleagues on internal initiatives.
  • Research issues and support the company in providing legal advice to internal clients.
  • Manage outside counsel resourcing and budgets for complex or nuanced areas of law, regulation, or policy.
  • Lead or support internal investigations on behalf of Legal and lead or support external investigations or litigation, independently, collaboratively, and/or with outside counsel as applicable.
  • Potentially manage one or more legal teams, such as Contracts, and/or direct reports, currently or as hired.
Desired Qualifications
  • Law firm experience is preferred, with a preference for experience advising pharmaceutical or biopharmaceutical companies.
  • Product launch experience is strongly preferred.
  • Buy-and-bill experience is a plus.
  • Litigation experience is a plus.

About the company

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Get referred to Invivyd

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PEMGARDA revenue grew 22% year over year in Q1 2026.
  • Invivyd completed LIBERTY enrollment June 16, 2026, accelerating VYD2311 decision-making.
  • Marc Elia became CEO on September 1, 2026, signaling urgency after trial progress.

What critics are saying

  • Invivyd disclosed substantial doubt about continuing as a going concern in August 2026.
  • PEMGARDA's EUA terminates June 29, 2027, threatening Invivyd's main revenue engine.
  • VYD2311 still faces Phase 3, FDA, and commercialization uncertainty after Q3 2026 data.

What makes Invivyd unique

  • Invivyd pairs surveillance-driven antibody design with rapid COVID variant updating.
  • PEMGARDA serves immunocompromised patients needing vaccine alternatives, a niche big pharmas ignore.
  • VYD2311 targets intramuscular prophylaxis, potentially improving access versus infusion-only antibodies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Professional Development Budget
  • Flexible Work Hours

Company News

Yahoo Finance
May 18th, 2026
Invivyd reports $13.7M Q1 revenue, 22% growth, advances COVID-19 monoclonal antibody trial

Invivyd Inc. reported first-quarter earnings on 14 May, with PEMGARDA net product revenue reaching $13.7 million, up 22% year-on-year. The biopharmaceutical company ended the quarter with $184.2 million in cash, supplemented by approximately $20 million from an at-the-market offering in April. The company posted a net loss of $41.4 million, driven by increased operating expenses related to its DECLARATION Phase 3 clinical trial for VYD2311, a COVID-19 monoclonal antibody candidate. The trial achieved initial full enrollment in March, with top-line data now expected in the third quarter. Invivyd is preparing additional Phase 3 trials and advancing its pipeline beyond COVID-19, including VMS063 for measles and VBY329 for paediatric respiratory syncytial virus prophylaxis.

Yahoo Finance
May 14th, 2026
Invivyd reports 22% YoY PEMGARDA revenue growth amid clinical trial investments

Invivyd Inc reported strong revenue growth in its Q1 2026 earnings call, with monoclonal antibody revenues continuing to grow and PEMGARDA revenue increasing 22% year-over-year compared to Q1 2025. The company accelerated recruitment for its pivotal DECLARATION trial, exceeding internal expectations, though recruitment slowed during a lull in COVID-19 cases. The company confirmed virus neutralisation against the Omicron BA.3.2 variant and is expanding its early discovery pipeline to include antibodies for measles, mumps, rubella and Lyme disease. Invivyd reported significant clinical spending on the DECLARATION trial but expects R&D spending to normalise as the VYD2311 trial concludes. The company strengthened its cash position through additional funding raised in April and received positive feedback from policymakers on increased government affairs activity.

Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.